| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Pertuzumab |
| Brand | Perjeta® |
| Indication | Is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early-stage BC at high risk of recurrence. |
| Assessment Process | |
| Rapid review commissioned | 10/08/2015 |
| Rapid review completed | 01/09/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full submission received from Applicant | 17/11/2015 |
| NCPE assessment completed | 10/05/2016 |
| NCPE assessment outcome | Reimbursement not Recommended |
Following NCPE assessment of the Applicant’s submission, cost effectiveness of pertuzumab (Perjeta®) (in combination with trastuzumab and chemotherapy) for this indication has not been demonstrated. Therefore it is not recommended for reimbursement.
Reimbursement was approved for this indication following confidential price negotiations July 2020.
